Welcome to our dedicated page for Rezolute news (Ticker: RZLT), a resource for investors and traders seeking the latest updates and insights on Rezolute stock.
Rezolute, Inc. develops therapies for rare and metabolic diseases, with recent company updates centered on hypoglycemia caused by hyperinsulinism. Its principal news themes include ersodetug, the Phase 3 sunRIZE study in congenital hyperinsulinism, the Phase 3 upLIFT study in tumor hyperinsulinism, and clinical evidence from continuous glucose monitoring, biomarker analyses and expanded access experience.
Rezolute news also covers FDA interactions, presentations at pediatric endocrinology and life sciences meetings, quarterly financial results, business updates and investor conference participation. The company’s updates generally connect clinical-program progress with regulatory engagement, cash resources and development priorities for its hyperinsulinism pipeline.
Rezolute (Nasdaq:RZLT) will deliver four presentations at the Endocrine Society’s ENDO 2026 meeting in Chicago from June 13-16, 2026.
The schedule includes an oral presentation of Phase 3 sunRIZE top-line results for congenital hyperinsulinism and three posters covering congenital and tumor hyperinsulinism outcomes and ersodetug (RZ358) clinical experience.
Rezolute (Nasdaq:RZLT) reported positive interim data from its open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. The trial is 50% enrolled, with 8 of 16 planned participants.
According to Rezolute, 6 of 8 participants met the primary endpoint responder criterion and fully discontinued intravenous glucose. Ersodetug has been well-tolerated with no drug-related adverse events reported. Topline results are expected in the second half of 2026.
Rezolute (Nasdaq:RZLT) reported fiscal Q3 2026 results and clinical updates for ersodetug in hyperinsulinism.
Expanded Phase 3 sunRIZE analyses in congenital HI showed CGM-based reductions in hypoglycemia and increased normoglycemia exposure versus placebo. FDA held a Type B meeting and encouraged submission of comprehensive datasets. Tumor HI Phase 3 upLIFT enrollment continues, with topline data expected in 2H 2026.
Cash and investments were $120.3M at March 31, 2026, versus $167.9M at June 30, 2025. Q3 R&D was $11.4M, G&A $6.0M, and net loss $16.2M, all improving or increasing versus the prior-year quarter as specified.
Rezolute (Nasdaq:RZLT), a late-stage rare disease company focused on treating hypoglycemia from hyperinsulinism, announced participation in two upcoming investor conferences.
Management will join the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, and the Jefferies Global Healthcare Conference from June 2-4, 2026, for fireside chats and one-on-one meetings.
Rezolute (Nasdaq: RZLT) presented expanded Phase 3 sunRIZE analyses at the Pediatric Endocrine Society on May 1, 2026, reporting consistent CGM-based glycemic improvements with ersodetug versus placebo across multiple pre-specified and post-hoc endpoints.
OLE participation was high (59 completers; 57 remain), and FDA requested submission of broader study data after a March 17 Type B meeting.
Rezolute (Nasdaq: RZLT) will present Phase 3 sunRIZE results for ersodetug in congenital hyperinsulinism at the Pediatric Endocrine Society Annual Meeting, April 30–May 3, 2026 in San Francisco. The oral presentation on May 1, 2026, 8:15–9:15 a.m. PT will include topline, pre-specified, and post-hoc analyses, with Diva D. De León-Crutchlow, MD, MSCE as presenter.
The company says the additional analyses continue to demonstrate target engagement and therapeutic benefit of ersodetug; attendees can consult the PES schedule for details.
Rezolute (Nasdaq: RZLT) reported outcomes from an FDA Type B meeting on March 17, 2026, for sunRIZE, a Phase 3 ersodetug study for congenital hyperinsulinism. The pivotal trial did not meet its primary endpoint versus placebo, though consistent CGM-based improvements and pharmacologic activity were observed.
FDA encouraged submission of full study reports and datasets for independent review and did not dismiss the program; Rezolute expects an update in the second half of 2026.
Rezolute (Nasdaq: RZLT) announced management will participate in the Citizens Life Sciences Conference on March 10-11, 2026 in Miami, FL.
Management plans one-on-one investor meetings throughout the conference; investors should contact their Citizens representative to schedule meetings with the Rezolute team.
Rezolute (Nasdaq: RZLT) reported Q2 fiscal 2026 results and a program update on Feb 12, 2026. The Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism did not meet its primary or key secondary endpoints, though some biomarker and CGM signals were observed.
The company achieved pharmacologic drug concentrations, all 59 completers entered the open‑label extension, and an FDA meeting under Breakthrough Therapy Designation is planned before end of Q1. Tumor HI upLIFT enrollment is ongoing with topline data expected H2 2026. Cash was $132.9M (Dec 31, 2025). Q2 net loss was $22.8M versus $15.7M year‑ago.
Rezolute (Nasdaq: RZLT) announced management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026 in New York. Management will hold one-on-one investor meetings during the conference. Investors should contact their Guggenheim representative to schedule meetings.